Brief: Kineta Announces Positive Kva12123 Monotherapy Safety And Biomarker Data From Its Ongoing Phase 1/2 Vista-101 Clinical Trial
03/10/2023 14:10
Oct 3 (Reuters) - Kineta Inc KA.O :
* KINETA ANNOUNCES POSITIVE KVA12123 MONOTHERAPY SAFETY AND
BIOMARKER DATA FROM ITS ONGOING PHASE 1/2 VISTA-101 CLINICAL
TRIAL
* KINETA INC - INITIAL MONOTHERAPY CLINICAL EFFICACY DATA
ANTICIPATED IN Q4 2023
* KINETA INC - ABOUT 90% VISTA RECEPTOR OCCUPANCY OBSERVED
IN 30
MG DOSING COHORT
* KINETA INC - CLINICAL TRIAL IS ADVANCING TO HIGHER
MONOTHERAPY
DOSE LEVELS AND IN COMBINATION WITH PEMBROLIZUMAB
Source text for Eikon: ID:nGNX9Sly7J
Further company coverage: KA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kineta
See all newsBrief: TuHURA Biosciences And Kineta Stockholders Approve Proposed Merger And All Related Proposals
Brief: Kineta Updates KVA12123 Clinical Results From Ongoing Phase 1/2 Vista101 Study At Society For Immunotherapy Of Cancer
U.S. STOCKS ON THE MOVE-Copper miners, Palo Alto Networks, Lowe's
U.S. STOCKS ON THE MOVE-Lineage, J.B. Hunt, McDonald's
Kineta rises on resuming enrollment in early-stage cancer study